These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 26156589)

  • 21. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
    Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
    Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient and allele-specific genome editing of disease loci in human iPSCs.
    Smith C; Abalde-Atristain L; He C; Brodsky BR; Braunstein EM; Chaudhari P; Jang YY; Cheng L; Ye Z
    Mol Ther; 2015 Mar; 23(3):570-7. PubMed ID: 25418680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
    Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH
    Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correction of β-thalassemia mutant by base editor in human embryos.
    Liang P; Ding C; Sun H; Xie X; Xu Y; Zhang X; Sun Y; Xiong Y; Ma W; Liu Y; Wang Y; Fang J; Liu D; Songyang Z; Zhou C; Huang J
    Protein Cell; 2017 Nov; 8(11):811-822. PubMed ID: 28942539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic correction of haemoglobin E in an immortalised haemoglobin E/beta-thalassaemia cell line using the CRISPR/Cas9 system.
    Trakarnsanga K; Thongsin N; Metheetrairut C; Tipgomut C; Poldee S; Wattanapanitch M
    Sci Rep; 2022 Sep; 12(1):15551. PubMed ID: 36114353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.
    Burnight ER; Gupta M; Wiley LA; Anfinson KR; Tran A; Triboulet R; Hoffmann JM; Klaahsen DL; Andorf JL; Jiao C; Sohn EH; Adur MK; Ross JW; Mullins RF; Daley GQ; Schlaeger TM; Stone EM; Tucker BA
    Mol Ther; 2017 Sep; 25(9):1999-2013. PubMed ID: 28619647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs.
    Sun N; Zhao H
    Biotechnol Bioeng; 2014 May; 111(5):1048-53. PubMed ID: 23928856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause Different Genome Instability in β-Thalassemia Induced Pluripotent Stem Cells (iPSCs).
    Ma N; Shan Y; Liao B; Kong G; Wang C; Huang K; Zhang H; Cai X; Chen S; Pei D; Chen N; Pan G
    J Biol Chem; 2015 May; 290(19):12079-89. PubMed ID: 25795783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of β
    Fang Y; Cheng Y; Lu D; Gong X; Yang G; Gong Z; Zhu Y; Sang X; Fan S; Zhang J; Zeng F
    Cell Prolif; 2018 Dec; 51(6):e12491. PubMed ID: 30070404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.
    Hoban MD; Lumaquin D; Kuo CY; Romero Z; Long J; Ho M; Young CS; Mojadidi M; Fitz-Gibbon S; Cooper AR; Lill GR; Urbinati F; Campo-Fernandez B; Bjurstrom CF; Pellegrini M; Hollis RP; Kohn DB
    Mol Ther; 2016 Sep; 24(9):1561-9. PubMed ID: 27406980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.
    Tang ZH; Chen JR; Zheng J; Shi HS; Ding J; Qian XD; Zhang C; Chen JL; Wang CC; Li L; Chen JZ; Yin SK; Huang TS; Chen P; Guan MX; Wang JF
    Stem Cells Transl Med; 2016 May; 5(5):561-71. PubMed ID: 27013738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic disruption of the KLF1 gene to overexpress the γ-globin gene using the CRISPR/Cas9 system.
    Shariati L; Khanahmad H; Salehi M; Hejazi Z; Rahimmanesh I; Tabatabaiefar MA; Modarressi MH
    J Gene Med; 2016 Oct; 18(10):294-301. PubMed ID: 27668420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation and Characterization of a MYF5 Reporter Human iPS Cell Line Using CRISPR/Cas9 Mediated Homologous Recombination.
    Wu J; Hunt SD; Xue H; Liu Y; Darabi R
    Sci Rep; 2016 Jan; 6():18759. PubMed ID: 26729410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene correction of HBB mutations in CD34
    Antony JS; Latifi N; Haque AKMA; Lamsfus-Calle A; Daniel-Moreno A; Graeter S; Baskaran P; Weinmann P; Mezger M; Handgretinger R; Kormann MSD
    Mol Cell Pediatr; 2018 Nov; 5(1):9. PubMed ID: 30430274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of gene editing strategies for human β-globin (HBB) gene mutations.
    Kalkan BM; Kala EY; Yuce M; Karadag Alpaslan M; Kocabas F
    Gene; 2020 Apr; 734():144398. PubMed ID: 31987908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice.
    Wang Y; Zheng CG; Jiang Y; Zhang J; Chen J; Yao C; Zhao Q; Liu S; Chen K; Du J; Yang Z; Gao S
    Cell Res; 2012 Apr; 22(4):637-48. PubMed ID: 22310243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
    Pavani G; Fabiano A; Laurent M; Amor F; Cantelli E; Chalumeau A; Maule G; Tachtsidi A; Concordet JP; Cereseto A; Mavilio F; Ferrari G; Miccio A; Amendola M
    Blood Adv; 2021 Mar; 5(5):1137-1153. PubMed ID: 33635334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of SOX6 gene using CRISPR/Cas9 technology for gamma-globin reactivation: An approach towards gene therapy of β-thalassemia.
    Shariati L; Rohani F; Heidari Hafshejani N; Kouhpayeh S; Boshtam M; Mirian M; Rahimmanesh I; Hejazi Z; Modarres M; Pieper IL; Khanahmad H
    J Cell Biochem; 2018 Nov; 119(11):9357-9363. PubMed ID: 30010219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy.
    Turan S; Farruggio AP; Srifa W; Day JW; Calos MP
    Mol Ther; 2016 Apr; 24(4):685-96. PubMed ID: 26916285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.